Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C.

Cleve Clin J Med

Inova Transplant Center, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA.

Published: May 2004

Neuropsychiatric side effects are common with interferon-based therapy for chronic hepatitis C, and their prompt recognition and management is essential to effective patient care. Depression induced by interferon has been a significant cause of early treatment discontinuation in clinical trials. The need to monitor for and treat interferon-induced depression is well established, but whether to use antidepressants prophylactically remains controversial. Nonetheless, clinicians should maintain a low threshold for antidepressant therapy. Other significant neuropsychiatric side effects include anxiety, hypomania or mania, fatigue, and cognitive dysfunction. These can be additional sources of patient distress during interferon therapy and require appropriate intervention through patient education, psychotropic medications, support, and behavioral techniques.

Download full-text PDF

Source
http://dx.doi.org/10.3949/ccjm.71.suppl_3.s27DOI Listing

Publication Analysis

Top Keywords

neuropsychiatric side
12
side effects
12
interferon-based therapy
8
managing neuropsychiatric
4
effects interferon-based
4
therapy
4
therapy hepatitis
4
hepatitis neuropsychiatric
4
effects common
4
common interferon-based
4

Similar Publications

Alzheimer's disease (AD) is a common central neurodegenerative disease disorder characterized primarily by cognitive impairment and non-cognitive neuropsychiatric symptoms that significantly impact patients' daily lives and behavioral functioning. The pathogenesis of AD remains unclear and current Western medicines treatment are purely symptomatic, with a singular pathway, limited efficacy, and substantial toxicity and side effects. In recent years, as research into AD has deepened, there has been a gradual increase in the exploration and application of medicinal plants for the treatment of AD.

View Article and Find Full Text PDF

Alpha6-containing GABA receptors - Novel targets for the treatment of schizophrenia.

Pharmacol Res

January 2025

Center for Brain Research, Department of Molecular Neurosciences, Medical University Vienna, Vienna, Austria. Electronic address:

α6-containing GABA receptors (α6GABARs) are strongly expressed in cerebellar granule cells and are of central importance for cerebellar functions. The cerebellum not only is involved in regulation of motor activity, but also in regulation of thought, cognition, emotion, language, and social behavior. Activation of α6GABARs enhances the precision of sensory inputs, enables rapid and coordinated movement and adequate responses to the environment, and protects the brain from information overflow.

View Article and Find Full Text PDF

Tourette syndrome (TS) is a neuropsychiatric disorder characterized by chronic motor and phonic tics, with a higher prevalence among boys. This condition can significantly impact patients' learning and daily life. Due to the limited efficacy and potential side effects of pharmacological treatments for TS, there is a critical need to develop novel, tailored therapeutic strategies.

View Article and Find Full Text PDF

Streptococcus mutans, the causative agent of human dental caries, expresses a cell wall attached Serotype c-specific Carbohydrate (SCC) that is critical for cell viability. SCC consists of a polyrhamnose backbone of →3)α-Rha(1 → 2)α-Rha(1→ repeats with glucose (Glc) side-chains and glycerol phosphate (GroP) decorations. This study reveals that SCC has one predominant and two more minor Glc modifications.

View Article and Find Full Text PDF

Ciprofloxacin is an antibiotic from the fluoroquinolone group that is frequently used in many clinical practices. In addition to its peripheral neuropathic side effects, it is an antibiotic that can pass through the blood-brain barrier due to its lipophilic features and cause rare central nervous system symptoms. Although cases of neuropsychiatric symptoms developing after treatment with ciprofloxacin have been reported in the literature, the number of reports of manic episodes after ciprofloxacin use is limited, and there have been no reports of delirious mania developing after ciprofloxacin use until the case presented in this report.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!